New drug trial aims to ease sudden heart failure in hospitalized patients
NCT ID NCT06556810
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests whether the drug atibuclimab (IC14) is safe and helpful for adults hospitalized with sudden worsening heart failure. Ten participants receive one IV dose of the drug and are monitored for side effects, drug levels, and heart failure markers. The goal is to gather initial safety and effectiveness data, with no placebo group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE DECOMPENSATED HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Virginia Commonwealth University
Richmond, Virginia, 23298, United States